Mitochondrial DNA copy number in colorectal cancer: Between tissue comparisons, clinicopathological characteristics and survival

Carcinogenesis

Volumn 36, Issue 12, 2015, Pages 1502-1510

  van Osch, Frits H M ^a   Voets, An M ^a   Schouten, Leo J ^a   Gottschalk, Ralph W H ^a   Simons, Colinda C J M ^a   van Engeland, Manon ^a   Lentjes, Marjolein H F M ^a   van den Brandt, Piet A ^a   Smeets, Hubert J M ^a   Weijenberg, Matty P ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA;

ADENOMA; AGED; COLORECTAL TUMOR; COMPARATIVE STUDY; COPY NUMBER VARIATION; FEMALE; GENE DOSAGE; GENETICS; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY;

ADENOMA; AGED; COLORECTAL NEOPLASMS; DNA COPY NUMBER VARIATIONS; DNA, MITOCHONDRIAL; FEMALE; GENE DOSAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 84949810352     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv151     Document Type: Article

References (56)

1. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
2. Kim, J.W. et al. (2006) Cancer's molecular sweet tooth and the Warburg effect. Cancer Res., 66, 8927-8930.
3. Warburg, O. (1956) On the origin of cancer cells. Science, 123, 309-314.
4. Green, D.R. et al. (1998) Mitochondria and apoptosis. Science, 281, 1309-1312.
5. Clay Montier, L.L. et al. (2009) Number matters: control of mammalian mitochondrial DNA copy number. J. Genet. Genomics, 36, 125-131.
6. Chen, D. et al. (2006) The p53 pathway promotes efficient mitochondrial DNA base excision repair in colorectal cancer cells. Cancer Res., 66, 3485-3494.
7. Tang, Y. et al. (2000) Rearrangements of human mitochondrial DNA (mtDNA): new insights into the regulation of mtDNA copy number and gene expression. Mol. Biol. Cell, 11, 1471-1485.
8. Moraes, C.T. (2001) What regulates mitochondrial DNA copy number in animal cells? Trends Genet., 17, 199-205.
9. Capps, G.J. et al. (2003) A model of the nuclear control of mitochondrial DNA replication. J. Theor. Biol., 221, 565-583.
10. Lin, P.C. et al. (2008) Expression of beta-F1-ATPase and mitochondrial transcription factor A and the change in mitochondrial DNA content in colorectal cancer: clinical data analysis and evidence from an in vitro study. Int. J. Colorectal Dis., 23, 1223-1232.
11. Chen, T. et al. (2011) The mitochondrial DNA 4,977-bp deletion and its implication in copy number alteration in colorectal cancer. BMC Med. Genet., 12, 8.
12. Chang, S.C. et al. (2009) Mitochondrial D-loop mutation is a common event in colorectal cancers with p53 mutations. Int. J. Colorectal Dis., 24, 623-628.
13. Feng, S. et al. (2011) Correlation between increased copy number of mitochondrial DNA and clinicopathological stage in colorectal cancer. Oncol. Lett., 2, 899-903.
14. Cui, H. et al. (2013) Association of decreased mitochondrial DNA content with the progression of colorectal cancer. BMC Cancer, 13, 110.
15. Park, S.Y. et al. (2004) Resistance of mitochondrial DNA-depleted cells against cell death: role of mitochondrial superoxide dismutase. J. Biol. Chem., 279, 7512-7520.
16. Pelicano, H. et al. (2006) Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J. Cell Biol., 175, 913-923.
17. Yu, M. et al. (2010) Decreased copy number of mitochondrial DNA in Ewing's sarcoma. Clin. Chim. Acta., 411, 679-683.
18. Lin, C.S. et al. (2008) Low copy number and low oxidative damage of mitochondrial DNA are associated with tumor progression in lung cancer tissues after neoadjuvant chemotherapy. Interact. Cardiovasc. Thorac. Surg., 7, 954-958.
19. Yamada, S. et al. (2006) Correlation between copy number of mitochondrial DNA and clinico-pathologic parameters of hepatocellular carcinoma. Eur. J. Surg. Oncol., 32, 303-307.
20. Bai, R.K. et al. (2011) Mitochondrial DNA content varies with pathological characteristics of breast cancer. J. Oncol., 2011, 496189.
21. Yu, M. et al. (2007) Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients. IUBMB Life, 59, 450-457.
22. Phipps, A.I. et al. (2013) KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br. J. Cancer, 108, 1757-1764.
23. Yokota, T. et al. (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br. J. Cancer, 104, 856-862.
24. Guastadisegni, C. et al. (2010) Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur. J. Cancer, 46, 2788-2798.
25. De Roock, W. et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet. Oncol., 11, 753-762.
26. Melotte, V. et al. (2009) N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J. Natl. Cancer Inst., 101, 916-927.
27. Dukes, CE. (1932) The classification of cancer of the rectum. J. Pathol. Bacteriol., 35, 323-332.
28. Meyer, R.M. et al.; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group. (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N. Engl. J. Med., 366, 399-408.
29. van den Brandt, P.A. et al. (1990) A large-scale prospective cohort study on diet and cancer in The Netherlands. J. Clin. Epidemiol., 43, 285-295.
30. Van den Brandt, P.A. et al. (1990) Development of a record linkage protocol for use in the Dutch Cancer Registry for Epidemiological Research. Int. J. Epidemiol., 19, 553-558.
31. Brink, M. et al. (2003) K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis, 24, 703-710.
32. de Vogel, S. et al. (2009) MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events. Ann. Oncol., 20, 1216-1222.
33. Hughes, L.A. et al. (2012) Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis. Int. J. Epidemiol., 41, 1060-1072.
34. Suraweera, N. et al. (2002) Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology, 123, 1804-1811.
35. Hoang, J.M. et al. (1997) BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res., 57, 300-303.
36. Fliss, M.S. et al. (2000) Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science, 287, 2017-2019.
37. Hanrahan, V. et al. (2003) The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J. Pathol., 200, 183-194.
38. Denko, N.C. (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer, 8, 705-713.
39. Mambo, E. et al. (2005) Tumor-specific changes in mtDNA content in human cancer. Int. J. Cancer, 116, 920-924.
40. Capuano, F. et al. (1997) Oxidative phosphorylation enzymes in normal and neoplastic cell growth. J. Bioenerg. Biomembr., 29, 379-384.
41. Meierhofer, D. et al. (2004) Decrease of mitochondrial DNA content and energy metabolism in renal cell carcinoma. Carcinogenesis, 25, 1005-1010.
42. Tumor Grade Fact Sheet. http://www.cancer.gov/cancertopics/factsheet/ detection/tumor-grade. 16 September 2015, date last accessed.
43. Lochhead, P. et al. (2013) Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J. Natl. Cancer Inst. 105, 1151-1156.
44. Hoeflich, K.P. et al. (2006) Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res., 66, 999-1006.
45. Safaee Ardekani, G. et al. (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and metaanalysis. PLoS One, 7, e47054.
46. Hung, W.Y. et al. (2012) Mitochondrial dysfunction promotes cell migration via reactive oxygen species-enhanced ß5-integrin expression in human gastric cancer SC-M1 cells. Biochim. Biophys. Acta, 1820, 1102-1110.
47. Popat, S. et al. (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol., 23, 609-618.
48. Walther, A. et al. (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat. Rev. Cancer, 9, 489-499.
49. Demory, M.L. et al. (2009) Epidermal growth factor receptor translocation to the mitochondria: regulation and effect. J. Biol. Chem., 284, 36592-36604.
50. Chun, S.Y. et al. (2010) Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1a and HIF-2a target genes. Mol. Cancer, 9, 293.
51. Lee, J.H. et al. (2015) Genetic characteristics of mitochondrial DNA was associated with colorectal carcinogenesis and its prognosis. PLoS One, 10, e0118612.
52. de Vogel, S. et al. (2009) MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events. Ann. Oncol., 20, 1216-1222.
53. Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487, 330-337.
54. Jose, C. et al. (2011) Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma? Biochim. Biophys. Acta, 1807, 552-561.
55. Zhang, Y.J. et al. (2009) mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann. Surg. Oncol., 16, 2617-2628.
56. Semenza, G.L. (2010) HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev., 20, 51-56.